2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMOCompleted
Our primary objectives are to decode **signatures** of activity from the electrode that might prelude or accompany an OCD attack, by analyzing its activity in an experimental setting and in real-life situations, and to correlate symptom changes with…